This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Duloxetine
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict NOT-RELEVANT HIGH
No indication for users in this archetype. Better-tolerated than venlafaxine but similar emotional/sexual side effects. Pain dual-indication (DPN, fibromyalgia, chronic LBP) is unique value but a user in this archetype has no pain syndrome.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, high cognitive workload (this-archetype) | NOT-RELEVANT | — |
30-50, executive maintenance | NOT-RELEVANT | unless mood + pain comorbidity. |
50+, mild cognitive decline | NOT-RELEVANT | for cognition. |
Anxiety-prone | OPTIONAL-ADD | if SSRI fails or if comorbid pain. |
High athletic load, tested status | SKIP-FOR-NOW | Same drive/libido concerns; hepatotoxicity risk if drinking. |
Sleep-disordered | SKIP-FOR-NOW | — |
Recovery-focused (post-injury, post-illness) | OPTIONAL | if neuropathic pain develops; otherwise gabapentin/pregabalin first-line for that indication. |
Strength/anabolic-focused | SKIP-PERMANENT | — |
- ★20-30, brain-priority, high cognitive workload (this-archetype)NOT-RELEVANT
- 30-50, executive maintenanceNOT-RELEVANT
unless mood + pain comorbidity.
- 50+, mild cognitive declineNOT-RELEVANT
for cognition.
- Anxiety-proneOPTIONAL-ADD
if SSRI fails or if comorbid pain.
- High athletic load, tested statusSKIP-FOR-NOW
Same drive/libido concerns; hepatotoxicity risk if drinking.
- Sleep-disorderedSKIP-FOR-NOW
- Recovery-focused (post-injury, post-illness)OPTIONAL
if neuropathic pain develops; otherwise gabapentin/pregabalin first-line for that indication.
- Strength/anabolic-focusedSKIP-PERMANENT
▸ Subjective experience (deep)
Same SSRI/SNRI emotional blunting and sexual dysfunction. Often nausea early. Pain effect emerges 1-4 weeks. Sedation or activation variable. Withdrawal milder than venlafaxine but real (dizziness, brain zaps).
▸ Tolerance + cycling deep dive
- Tolerance: Maintained for most.
- Not cycled.
▸ Stacking deep dive
Avoid stacking with
- MAOIs.
- Strong CYP1A2 inhibitors (ciprofloxacin, fluvoxamine) → 2-5x ↑ duloxetine exposure.
- Hepatotoxic agents (acetaminophen at high cumulative doses, alcohol).
▸ Drug interactions deep dive
CYP1A2 + CYP2D6 substrate. Moderate CYP2D6 inhibitor (less than fluoxetine, more than escitalopram). Watch with TCAs, antipsychotics, codeine.
▸ Pharmacogenomics
CYP2D6 + CYP1A2 phenotypes both relevant. Smokers (CYP1A2 inducers) have lower exposure.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Rx | Pharmacy | $10-30/mo generic | high | Generic widely available. |
▸ Biomarkers to track (deep)
- Baseline: PHQ-9, GAD-7, LFTs, BP, sodium.
- During use: PHQ-9 q4-6 weeks; LFTs if symptoms or alcohol use; BP every visit.
- Post-discontinuation: Withdrawal symptom diary.
▸ Controversies / open debates Live debate
- Pain effect size: NNT ~4-7 for clinically meaningful pain reduction in DPN/fibromyalgia — modest but real.
- Hepatotoxicity signal: FDA labeling cautions against alcohol; case reports of fulminant failure rare but documented.
- Withdrawal underestimated: Patient communities report longer/worse withdrawal than clinical guidelines acknowledge.
▸ Verdict change log
- 2026-05-06 — Initial verdict: NOT-RELEVANT.
▸ Open questions / gaps Open
Whether dual mood + pain mechanism produces meaningful synergy vs separate optimization (SSRI + gabapentinoid).
References
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.